<DOC>
	<DOCNO>NCT01443260</DOCNO>
	<brief_summary>The purpose study determine whether GL-ONC1 , attenuate vaccinia virus , safe administer patient peritoneal carcinomatosis via infusion within abdominal cavity implant catheter . The study seek also arrive recommend dose schedule future investigation , evidence anti-tumor activity , detection virus body fluid , analysis viral delivery tumor normal cell , evaluate antibody response vaccinia virus .</brief_summary>
	<brief_title>A Study GL-ONC1 , Oncolytic Vaccinia Virus , Patients With Advanced Peritoneal Carcinomatosis</brief_title>
	<detailed_description>Peritoneal carcinomatosis include variety tumor extensive metastasis throughout peritoneal cavity ( inside surface abdomen ) find gall bladder , liver , colon , appendix , ovarian , pancreas , mesothelioma , pseudomyxoma peritonei , rectal , small bowel stomach cancer . It broadly include multiple tumor develop line peritoneal abdominal cavity lining . These tumor may difficult completely remove surgically may recur despite conventional systemic chemotherapy , thereby result poor patient outcome . In preclinical study , GL-ONC1 , oncolytic vaccinia virus , show ability preferentially locate , colonize destroy tumor cell 30 different human tumor . A Phase I clinical study focus safety tolerability GL-ONC1 intravenously administer patient variety solid tumor entity show GL-ONC1 well-tolerated therapeutic dose level , document evidence antitumor activity . This additional Phase I/II study seek evaluate GL-ONC1 administer repetitively every 4 week 4 cycle via infusion use implanted catheter peritoneal cavity . In Phase I , patient individually assess safety dose limit toxicity . The study aim Phase II portion continue collection safety information well define tolerability GL-ONC1 , well viral replication action effect GL-ONC1 human select dose level dose schedule future trial . Throughout phase study , anti-tumor effect evaluate .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Vaccinia</mesh_term>
	<criteria>1 . Diagnosis histologically cytologically document , advanced stage peritoneal carcinomatosis refractory standard therapy , exhibit likely survival &gt; 4 month judge clinically . 2 . Evidence measurable disease . 3 . Age ≥ 18 year . 4 . ECOG ( Eastern Cooperative Oncology Group Performance Status ) ≤ 2 . 5 . Required baseline laboratory data include : Absolute neutrophil count ( ANC ) ≥ 1.5 × 109/L . Platelets ≥ 75 ×109/L Haemoglobin ≥ 9.5 g/dL Serum creatinine ≤ 2 × upper limit normal ( ULN ) Total Bilirubin ≤ 5 × ULN AST/ALT ≤ 7.5 × ULN Negative pregnancy test female childbearing potential Serum albumin ≥ 2.5 g/dL . If serum albumin level &lt; 2.5/dL , albumin substitution take place threshold ≥ 2.5 g/dL . 6 . Willing able comply schedule visit , treatment plan , laboratory test , implantation indwell peritoneal catheter , well respective drainage procedure . 7 . All patient must agree use highly effective contraception . 1 . Patients exhibit objective evidence baseline brain metastasis exclude participate . 2 . Pregnant breastfeed woman . 3 . Primary tumor metastasis tissues/organs , clinical judgment , likely hinder survival least next 4 month . 4 . Patients fever , active immunosuppressive systemic infection suppress immune system , include know HIV , assess within 14 day prior study enrolment . 5 . Concurrent vaccination immunotherapy 28 day study therapy study treatment . 6 . Patients immunosuppressive therapy immune system disorder , include autoimmune disease . Concurrent steroid use equivalent 20 mg/day prednisolone allow . 7 . Prior splenectomy . 8 . Previous organ transplantation . 9 . Fully therapeutic coagulation therapy allow intraperitoneal insertion permanent catheter . 10 . Patients clinically significant dermatological disorder ( e.g. , eczema psoriasis ) , skin lesion ulcer , history atopic dermatitis , history Darier 's disease ( Keratosis Follicularis ) . 11 . Clinically significant cardiac disease ( New York Heart Association , Class III IV : see Appendix 10 ) 12 . Known allergy ovalbumin egg product . 13 . Concurrent use antiviral agent active vaccinia virus . 14 . Prior gene therapy treatment prior therapy cytolytic virus type .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>oncolytic virus</keyword>
	<keyword>oncolytic</keyword>
	<keyword>GL-ONC1</keyword>
	<keyword>Vaccinia</keyword>
	<keyword>Vaccinia virus</keyword>
	<keyword>Genelux</keyword>
	<keyword>Genelux GmbH</keyword>
	<keyword>peritoneal</keyword>
	<keyword>peritoneal carcinomatosis</keyword>
	<keyword>cancer</keyword>
	<keyword>abdominal cancer</keyword>
	<keyword>image</keyword>
</DOC>